Quốc gia: Singapore
Ngôn ngữ: Tiếng Anh
Nguồn: HSA (Health Sciences Authority)
ETHINYLESTRADIOL
MSD PHARMA (SINGAPORE) PTE. LTD.
G03AA
2.7 mg
INTRAUTERINE DEVICE
INTRAUTERINE
Prescription Only
ORGANON (IRELAND) LTD
2005-06-27
NuvaRing Vaginal Ring CCDS-MK8342A-RNG-102013 1. NAME OF THE MEDICINAL PRODUCT NuvaRing ® 0.120 mg/0.015 mg per 24 hours, vaginal ring 2. QUALITATIVE AND QUANTITATIVE COMPOSITION NuvaRing contains 11.7 mg etonogestrel and 2.7 mg ethinylestradiol. The ring releases etonogestrel and ethinylestradiol at an average amount of 0.120 mg and 0.015 mg, respectively for 24 hours, over a period of 3 weeks. For the full list of excipients, see Section 6.1. 3. PHARMACEUTICAL FORM Vaginal ring NuvaRing is a flexible, transparent, and colorless to almost colorless ring, with an outer diameter of 54 mm and a cross-sectional diameter of 4 mm. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Contraception 4.2 Posology and method of administration Posology To achieve contraceptive effectiveness, NuvaRing must be used as directed (see ‘How to use NuvaRing’ and 'How to start NuvaRing'). Paediatric population The safety and efficacy of NuvaRing in adolescents under the age of 18 have not been studied. 4.2.1 How to use NuvaRing The woman herself can insert NuvaRing in the vagina. The physician should advise the woman how to insert and remove NuvaRing. For insertion the woman should choose a position that is most comfortable for her, e.g. standing with one leg up, squatting, or lying down. NuvaRing should be compressed and inserted into the vagina until it feels comfortable. The exact position of NuvaRing in the vagina is not critical for the contraceptive effect of the ring ( see Figures 1-4 ). Once NuvaRing has been inserted (see ‘How to start NuvaRing’) it is left in the vagina continuously for 3 weeks. It is good habit for the woman to regularly verify the presence of NuvaRing. If NuvaRing is accidentally expelled, the w Đọc toàn bộ tài liệu